Protocols›Performance & endurance›Bodybuilding
← Protocols
Athlete / performance · uptakeCommunity · convergenceNo approved clinical use

Bodybuilding

Stack: Ipamorelin + CJC-1295 + MGF + IGF-1 LR3 · physique / periodised
"A periodised physique pattern off the GH axis plus IGF. Aggressive intent, weak human evidence — documented as a community reference, not a recommendation."
GoalPhysique / periodised
Compounds4 · Ipamorelin + CJC-1295 + MGF + IGF-1 LR3
Humans exposed (est.)Moderate — undocumented
StatusMHRA (UK): not licensed medicines here · FDA (US): not approved · weak human evidence — reference only
In this stack — snapshot; tap through for the full molecule file
Provenance & evidence layers — of the combination, not the parts
Athlete / performance
Where / who
Community / athlete and clinic use as tagged above.
Use status
Physique-circle convention.
Evidence it adds
Popularity / convention — not efficacy.
Basis: real-world uptake & convention — not trial data
US clinic · off-label compounding
Where / who
US functional-medicine, longevity & sports-medicine clinics — physician-prescribed via 503A/503B compounding pharmacies.
Track record
Ipamorelin / CJC-1295: among the most commonly compounded peptides in US clinics until the Sept 2023 FDA Category 2 listing; removed from Category 2 Apr 2026, 503A Bulks List decision pending the PCAC meeting 23–24 Jul 2026.
Evidence it adds
Real-world clinical observation — physician-charted, supervised use. A genuine evidence tier, but observational: uncontrolled, unpublished, no registry, outside formal pharmacovigilance.
What it means
Off-label compounding under prescription — never an FDA-approved therapy. Removal from Category 2 is not approval.
Basis: US compounding-pharmacy practice · FDA Docket FDA-2025-N-6895
No approved clinical use
Clinical record
No country lists this exact combination as an approved therapy.
Human trials
No completed human trial of the combination. Weak/absent human evidence.
Basis required for a clinical-use tag: none found — absence shown, not hidden
Why this combination

A GH-axis base (CJC-1295 + Ipamorelin) with MGF and IGF-1 LR3 layered for physique intent. The human evidence is weak to absent, and IGF-1 LR3 carries real risk. Presented as community reference only.

Members only · the actionable depth
See exactly how it's run
Doses, cycle structure and what to monitor are part of membership. The provenance, evidence and exposure above are always free.
Get TiQ1 · Free →
Free · just create an account
Cycle shape — how it's typically structured, not a schedule to follow
Loading
build up
Maintenance
hold / taper
Off
stop / reassess
Convention from community use, not a prescription.
What's worth monitoring

With limited or no human safety data for this combination, there is no established marker set to monitor against — which is a reason for more caution, not less. Baseline bloods and a clinician conversation matter here. General information, not medical advice.

Combination evidence
Real-world uptake Moderate

Physique-circle convention.

Human efficacy None

Weak/absent human evidence.

Clinical observation Observational

A decade-plus of physician-supervised, charted use — meaningful real-world signal, with no commonly-reported serious adverse-event pattern. But uncontrolled, unpublished, held in private charts (no registry) and outside formal pharmacovigilance. Not controlled evidence.

The honest ceiling

Popular in a niche, unproven and not without risk.

Fast facts
Compounds

Ipamorelin · CJC-1295 · MGF · IGF-1 LR3

Humans exposed (est.)

Moderate — undocumented.

UK strip

GREEN — research material